Latest article
Fierce Pharma Asia—AstraZeneca-Junshi PD-1 deal; Takeda’s $1.2B diabetes selloff, Ovid epilepsy collab pullout
In a strangely structured deal, AstraZeneca has nationwide licensed Junshi Biosciences' PD-1 inhibitor for only one indication in China. Takeda continued to sell...
Physician modified diabetes meds to keep away from too-low blood sugar | Information, Sports...
DEAR DOCTOR. ROACH: I have a question about medication. I will soon be 77 years old. I have had type 2...